Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist.
C Serradeil-Le Gal, … , J P Maffrand, G Le Fur
C Serradeil-Le Gal, … , J P Maffrand, G Le Fur
Published December 15, 1996
Citation Information: J Clin Invest. 1996;98(12):2729-2738. https://doi.org/10.1172/JCI119098.
View: Text | PDF
Research Article Article has an altmetric score of 6

Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist.

  • Text
  • PDF
Abstract

SR 121463A, a potent and selective, orally active, nonpeptide vasopressin V2 receptor antagonist, has been characterized in several in vitro and in vivo models. This compound displayed highly competitive and selective affinity for V2 receptors in rat, bovine and human kidney (0.6 < or = Ki [nM] < or = 4.1). In this latter preparation, SR 121463A potently antagonized arginine vasopressin (AVP)-stimulated adenylyl cyclase activity (Ki = 0.26+/-0.04 nM) without any intrinsic agonistic effect. In autoradiographic experiments performed in rat kidney sections, SR 121463A displaced [3H]AVP labeling especially in the medullo-papillary region and confirmed that it is a suitable tool for mapping V2 receptors. In comparison, the nonpeptide V2 antagonist, OPC-31260, showed much lower affinity for animal and human renal V2 receptors and lower efficacy to inhibit vasopressin-stimulated adenylyl cyclase (Ki in the 10 nanomolar range). Moreover, OPC-31260 exhibited a poor V2 selectivity profile and can be considered as a V2/V1a ligand. In normally hydrated conscious rats, SR 121463A induced powerful aquaresis after intravenous (0.003-0.3 mg/kg) or oral (0.03-10 mg/kg) administration. The effect was dose-dependent and lasted about 6 hours at the dose of 3 mg/kg p.o. OPC-31260 had a similar aquaretic profile but with markedly lower oral efficacy. The action of SR 121463A was purely aquaretic with no changes in urine Na+ and K+ excretions unlike that of known diuretic agents such as furosemide or hydrochlorothiazide. In addition, no antidiuretic properties have been detected with SR 121463A in vasopressin-deficient Brattleboro rats. Thus, SR 121463A is the most potent and selective, orally active V2 antagonist yet described and could be a powerful tool for exploring V2 receptors and the therapeutical usefulness of V2 blocker aquaretic agents in water-retaining diseases.

Authors

C Serradeil-Le Gal, C Lacour, G Valette, G Garcia, L Foulon, G Galindo, L Bankir, B Pouzet, G Guillon, C Barberis, D Chicot, S Jard, P Vilain, C Garcia, E Marty, D Raufaste, G Brossard, D Nisato, J P Maffrand, G Le Fur

×

Total citations by year

Year: 2021 2020 2019 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1995 1983 Total
Citations: 7 2 2 6 3 7 1 6 9 11 6 3 13 8 16 7 2 11 9 12 16 15 10 3 1 1 187
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (187)

Title and authors Publication Year
The Biology of Vasopressin
S Sparapani, C Millet-Boureima, J Oliver, K Mu, P Hadavi, T Kalostian, N Ali, CM Avelar, M Bardies, B Barrow, M Benedikt, G Biancardi, R Bindra, L Bui, Z Chihab, A Cossitt, J Costa, T Daigneault, J Dault, I Davidson, J Dias, E Dufour, S El-Khoury, N Farhangdoost, A Forget, A Fox, M Gebrael, MC Gentile, O Geraci, A Gnanapragasam, E Gomah, E Haber, C Hamel, T Iyanker, C Kalantzis, S Kamali, E Kassardjian, HK Kontos, TB Le, D LoScerbo, YF Low, DM Rae, F Maurer, S Mazhar, A Nguyen, K Nguyen-Duong, C Osborne-Laroche, HW Park, E Parolin, K Paul-Cole, LS Peer, M Philippon, CA Plaisir, JP Marroquin, S Prasad, R Ramsarun, S Razzaq, S Rhainds, D Robin, R Scartozzi, D Singh, SS Fard, M Soroko, NS Motlagh, K Stern, L Toro, MW Toure, S Tran-Huynh, S Trépanier-Chicoine, C Waddingham, AJ Weekes, A Wisniewski, C Gamberi
Biomedicines 2021
Synthesis of Six-Membered Spiro Azacyclic Oxindole Derivatives via a One-Pot Process of Umpolung Allylation/Aza-Prins Cyclization
WC Jang, M Jung, HM Ko
Organic letters 2021
Cryo–electron microscopy structure of the antidiuretic hormone arginine-vasopressin V2 receptor signaling complex
J Bous, H Orcel, N Floquet, C Leyrat, J Lai-Kee-Him, G Gaibelet, A Ancelin, J Saint-Paul, S Trapani, M Louet, R Sounier, H Déméné, S Granier, P Bron, B Mouillac
Science Advances 2021
Recent Advances in N‐Heterocyclic Carbene Catalyzed Oxidative Cyclization for the Formation of Heterocycles
T Pavithra, ES Devi, CU Maheswari
ASIAN J ORG CHEM 2021
Stereoselective synthesis and applications of spirocyclic oxindoles
AJ Boddy, JA Bull
Organic Chemistry Frontiers 2021
“ADPKD-omics”:Determinants of Cyclic AMP Levels in Renal Epithelial Cells
YR Mehta, SA Lewis, KT Leo, L Chen, E Park, V Raghuram, CL Chou, CR Yang, H Kikuchi, S Khundmiri, B Poll, MA Knepper
Kidney International 2021
“ADPKD-omics”: Determinants of Cyclic AMP Levels in Renal Epithelial Cells
Mehta YR, Lewis SA, Leo KT, Chen L, Park E, Raghuram V, Chou CL, Yang CR, Kikuchi H, Khundmiri S, Poll B, Knepper MA
Kidney International 2021
Phosphoproteomic Identification of Vasopressin/cAMP/Protein Kinase A–Dependent Signaling in Kidney
K Salhadar, A Matthews, V Raghuram, K Limbutara, CR Yang, A Datta, CL Chou, MA Knepper
Molecular pharmacology 2020
Intramolecular Dehydrogenative Coupling Approach to 2‐Oxindoles Using Fe(OAc) 2 /NaI/Na 2 S 2 O 8
J Zhao, X Song, D Li, J Zhao, J Qu, Y Zhou
European Journal of Organic Chemistry 2020
Tolvaptan activates the Nrf2/HO-1 antioxidant pathway through PERK phosphorylation
T Fujiki, F Ando, K Murakami, K Isobe, T Mori, K Susa, N Nomura, E Sohara, T Rai, S Uchida
Scientific Reports 2019
Modulation of proteostasis and protein trafficking: a therapeutic avenue for misfolded G protein-coupled receptors causing disease in humans
A Ulloa-Aguirre, JA Janovick
Emerging Topics in Life Sciences 2019
Voltage-gated Sodium Channels: Structure, Function and Channelopathies
M Chahine
2017
Voltage-gated Sodium Channels: Structure, Function and Channelopathies
M Chahine
2017
Voltage-gated Sodium Channels: Structure, Function and Channelopathies
M Chahine
2017
Small-Molecule Modulation of Protein Homeostasis
GM Burslem, CM Crews
Chemical Reviews 2017
Heart Failure
J Bauersachs, J Butler, P Sandner
Heart Failure 2017
Ligand recognition properties of the vasopressin V2 receptor studied under QSAR and molecular modeling strategies
M Martínez-Archundia, B Colín-Astudillo, LM Moreno-Vargas, G Ramírez-Galicia, R Garduño-Juárez, O Deeb, MC Contreras-Romo, A Quintanar-Stephano, E Abarca-Rojano, J Correa-Basurto
Chemical Biology & Drug Design 2017
Dehydration effects of a V2 antagonist on endolymphatic hydrops in guinea pigs
N Egami, A Kakigi, T Takeda, T Yamasoba
Hearing Research 2016
N -Heterocyclic Carbene Catalytic [4 + 2] Cyclization of 3-Alkylenyloxindoles with Enals: γ-Carbon Activation for Enantioselective Assembly of Spirocarbocyclic Oxindoles
H Yao, Y Zhou, X Chen, P Zhang, J Xu, H Liu
The Journal of Organic Chemistry 2016
Oxidative Dearomatic Cyclization of N-Substituted Benzanilide Derivatives: Conformational Effect of Amide Groups on the Reaction
J Takayama, T Sakamoto, K Hayashi, M Xuan, M Suda, H Teramae, Y Shimano
HETEROCYCLES 2016
How genetic errors in GPCRs affect their function: Possible therapeutic strategies
H Stoy, VV Gurevich
Genes & Diseases 2015
Effect of Small Molecule Vasopressin V 1a and V 2 Receptor Antagonists on Brain Edema Formation and Secondary Brain Damage following Traumatic Brain Injury in Mice
SM Krieg, S Sonanini, N Plesnila, R Trabold
Journal of Neurotrauma 2015
Mass-spectrometry-based method for screening of new peptide ligands for G-protein-coupled receptors
CT Cologna, N Gilles, J Echterbille, M Degueldre, D Servent, E Pauw, L Quinton
Analytical and Bioanalytical Chemistry 2015
Functional Amyloid Signaling via the Inflammasome, Necrosome, and Signalosome: New Therapeutic Targets in Heart Failure
TL Parry, JH Melehani, MJ Ranek, MS Willis
Frontiers in Cardiovascular Medicine 2015
Actualización en neuroendocrinología
CV Artero
2015
Diastereoselective Synthesis of Six-Membered Carbocyclic Spirooxindoles via 6π-Electrocyclization of 3-Dienylidene-2- oxindoles
KH Kim, HR Moon, J Lee, J Kim, JN Kim
Advanced synthesis & catalysis 2015
Multicolor time-resolved Förster resonance energy transfer microscopy reveals the impact of GPCR oligomerization on internalization processes
O Faklaris, M Cottet, A Falco, B Villier, M Laget, JM Zwier, E Trinquet, B Mouillac, JP Pin, T Durroux
The FASEB Journal 2015
Cellular Endocrinology in Health and Disease
AA Bremer, WL Miller
Cellular Endocrinology in Health and Disease 2014
The Concise Guide to PHARMACOLOGY 2013/14: G Protein-Coupled Receptors: G protein-coupled receptors
SP Alexander, HE Benson, E Faccenda, AJ Pawson, JL Sharman, M Spedding, JA Peters, AJ Harmar
British Journal of Pharmacology 2013
Enantioselective synthesis of spiro[cyclohexane-1,3′-indolin]-2′-ones containing multiple stereocenters via organocatalytic Michael/aldol cascade reactions
AK Ghosh, B Zhou
Tetrahedron Letters 2013
Stereoselective syntheses of functionalized spirocyclopenteneoxindoles via triphenylphosphine-catalyzed [3+2] cycloaddition reactions
QF Zhou, XP Chu, FF Ge, C Li, T Lu
Molecular Diversity 2013
Seldin and Giebisch's The Kidney
CJ Cooper, LD Dworkin, WL Henrich
Seldin and Giebisch's The Kidney 2013
Synthesis of Six-Membered Spirocyclic Oxindoles with Five Consecutive Stereocenters in an Asymmetric Organocatalytic One-Pot Michael/Michael/Aldol Addition Sequence
B Zhou, Y Yang, J Shi, Z Luo, Y Li
The Journal of Organic Chemistry 2013
Global analysis of the effects of the V2 receptor antagonist satavaptan on protein phosphorylation in collecting duct
JD Hoffert, T Pisitkun, F Saeed, JL Wilson, MA Knepper
American journal of physiology. Renal physiology 2013
Downregulation of vasopressin V1A receptors and activation of mitogen-activated protein kinase in rat mesangial cells cultured under high-glucose conditions
A Tahara, J Tsukada, Y Tomura, T Yatsu, M Shibasaki
Clinical and Experimental Pharmacology and Physiology 2012
Effects of High Glucose on AVP-Induced Hyperplasia, Hypertrophy, and Type IV Collagen Synthesis in Cultured Rat Mesangial Cells
A Tahara, J Tsukada, Y Tomura, T Yatsu, M Shibasaki
Endocrine Research 2012
Endoplasmic Reticulum Enrollment in Alzheimer’s Disease
RJ Viana, AF Nunes, CM Rodrigues
Molecular Neurobiology 2012
Genetics and diagnosis of central diabetes insipidus
DG Bichet
Annales d'Endocrinologie 2012
Analogue-Based Drug Discovery III: FISCHER:DRUG ANALOGS III O-BK
K Kondo, H Ogawa
Analogue-Based Drug Discovery III: FISCHER:DRUG ANALOGS III O-BK 2012
Oxytocin and vasopressin agonists and antagonists as research tools and potential therapeutics
M Manning, A Misicka, A Olma, K Bankowski, S Stoev, B Chini, T Durroux, B Mouillac, M Corbani, G Guillon
Journal of Neuroendocrinology 2012
Vaptans and hyponatremia in critical patients
D D'Auria, GZ Marinosci, GD Benedictis, O Piazza
Translational medicine @ UniSa 2012
Vaptans and Hyponatremia in Critical Patients
D D’Auria, GZ Marinosci, GD Benedictis, O Piazza
Translational medicine @ UniSa 2012
Subcellular Biochemistry
G Maya-Núñez, A Ulloa-Aguirre, JA Janovick, PM Conn
Sub-cellular biochemistry 2012
Arginine vasopressin (AVP) and treatment with arginine vasopressin receptor antagonists (vaptans) in congestive heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion (SIADH)
N Gassanov, N Semmo, M Semmo, AM Nia, U Fuhr, F Er
European Journal of Clinical Pharmacology 2011
G Protein-Coupled Receptors
British Journal of Pharmacology 2011
Vasopressin regulates rat mesangial cell growth by inducing autocrine secretion of vascular endothelial growth factor
A Tahara, J Tsukada, Y Tomura, T Yatsu, M Shibasaki
The Journal of Physiological Sciences 2011
Short- and long-term treatment of dilutional hyponatraemia with satavaptan, a selective arginine vasopressin V2-receptor antagonist: the DILIPO study
D Aronson, JG Verbalis, M Mueller, H Krum, A Alvarisqueta, J Bluguermann, RA Guerrero, L Howes, H Krum, A Sindone, G Decaux, A Soupart, DE Allaf, F Baillie, N Racine, S Logsetty, A Morales, F Gutierrez, N Gadsboll, C Dervenis, A Manolis, D Tsiftsis, T Forster, L Ujszaszy, C Farsang, D Aronson, S Efrati, D Freimark, D Zeltser, Z Gaciong, I Skoneczna, A Drzewiecki, P Miekus, M Piepiorka, L Providencia, C Fonseca, N Lousada, M Dorobantu, D Dimulescu, M Vintila, AG Dan, L Rotaru, B Minescu, D Zdrenghea, MM de Basson, JS Roos, A Roodt, G Wikstrom, ES Chung, SS Gottlieb, A Jain, DC Pan
European Journal of Heart Failure 2011
The potential role for lixivaptan in heart failure and in hyponatremia
HD Zmily, NS Khan, S Daifallah, JK Ghali
Expert Opinion on Investigational Drugs 2011
Vasopressin induces human mesangial cell growth via induction of vascular endothelial growth factor secretion
A Tahara, J Tsukada, Y Tomura, T Yatsu, M Shibasaki
Neuropeptides 2011
The Posterior Pituitary
DG Bichet
The Pituitary 2011
Williams Textbook of Endocrinology
DW Cooke, SA Divall, S Radovick
Williams Textbook of Endocrinology 2011
The Pituitary
X Bertagna, L Guignat, MC Raux-Demay, B Guilhaume, F Girard
The Pituitary 2011
Pharmacoperones: A New Therapeutic Approach for Diseases Caused By Misfolded G Protein-Coupled Receptors
A Ulloa-Aguirre, PM Conn
Recent patents on endocrine, metabolic & immune drug discovery 2011
Tolvaptan inhibits ERK-dependent cell proliferation, Cl − secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin
GA Reif, T Yamaguchi, E Nivens, H Fujiki, CS Pinto, DP Wallace
American journal of physiology. Renal physiology 2011
Arginine vasopressin receptor antagonists (vaptans): pharmacological tools and potential therapeutic agents
PT Veeraveedu, SS Palaniyandi, K Yamaguchi, Y Komai, RA Thandavarayan, V Sukumaran, K Watanabe
Drug Discovery Today 2010
An overview of satavaptan: a selective V2 receptor antagonist
J Farah, S Daifallah, H Zmily, JK Ghali
Therapy 2010
Organocatalytic Tandem Reaction to Construct Six-Membered Spirocyclic Oxindoles with Multiple Chiral Centres through a Formal [2+2+2] Annulation
K Jiang, ZJ Jia, S Chen, L Wu, YC Chen
Chemistry - A European Journal 2010
Vasopressin: A Review of Therapeutic Applications
NF Holt, KL Haspel
Journal of Cardiothoracic and Vascular Anesthesia 2010
Antagonistas del receptor de vasopresina: los vaptanes
C Villabona
Endocrinología y Nutrición 2010
xPharm: The Comprehensive Pharmacology Reference
A Vinh
xPharm: The Comprehensive Pharmacology Reference 2010
Identification, characterization and rescue of a novel vasopressin-2 receptor mutation causing nephrogenic diabetes insipidus
SA Ranadive, B Ersoy, H Favre, CC Cheung, SM Rosenthal, WL Miller, C Vaisse
Clinical Endocrinology 2009
cAMP-dependent chloride secretion mediates tubule enlargement and cyst formation by cultured mammalian collecting duct cells
R Montesano, H Ghzili, F Carrozzino, BC Rossier, E Féraille
American journal of physiology. Renal physiology 2009
Vasopressin and oxytocin
British Journal of Pharmacology 2009
VASOPRESSIN STIMULATES THE PRODUCTION OF EXTRACELLULAR MATRIX BY CULTURED RAT MESANGIAL CELLS
A Tahara, J Tsukada, Y Tomura, T Suzuki, T Yatsu, M Shibasaki
Clinical and Experimental Pharmacology and Physiology 2008
Pharmacology of vasopressin antagonists
LC Costello-Boerrigter, G Boerrigter, JC Burnett
Heart Failure Reviews 2008
Non-peptide arginine-vasopressin antagonists: the vaptans
G Decaux, A Soupart, G Vassart
The Lancet 2008
Treatment of Hyponatremia
P Gross
Internal Medicine 2008
Vasopressin Antagonists in the Treatment of Water-Retaining Disorders
S Kumar, T Berl
Seminars in Nephrology 2008
Hyponatriämie und Vaptane
C Palm, P Gross
Der Nephrologe 2008
Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities
I Kim, W Xu, JC Reed
Nature Reviews Drug Discovery 2008
Fluorescent agonists and antagonists for vasopressin/oxytocin G protein-coupled receptors: usefulness in ligand screening assays and receptor studies
B Mouillac, M Manning, T Durroux
Mini reviews in medicinal chemistry 2008
Studies in Natural Products Chemistry
M Seki
Studies in Natural Products Chemistry 2008
Différence de concentration urinaire selon le sexe ou l’origine ethnique : implications possibles dans la susceptibilité variable à différentes pathologies rénales et cardiovasculaires
J Perucca, N Bouby, P Valeix, P Jungers, L Bankir
Néphrologie & Thérapeutique 2008
Identification of novel selective V2 receptor non-peptide agonists
AL Tredici, KE Vanover, AE Knapp, SM Bertozzi, NR Nash, ES Burstein, J Lameh, EA Currier, RE Davis, MR Brann, N Mohell, R Olsson, F Piu
Biochemical Pharmacology 2008
Sodium Excretion in Response to Vasopressin and Selective Vasopressin Receptor Antagonists
J Perucca, DG Bichet, P Bardoux, N Bouby, L Bankir
Journal of the American Society of Nephrology : JASN 2008
Effects of Novel Vasopressin Receptor Antagonists on Renal Function and Cardiac Hypertrophy in Rats with Experimental Congestive Heart Failure
B Bishara, H Shiekh, T Karram, I Rubinstein, ZS Azzam, N Abu-Saleh, S Nitecki, J Winaver, A Hoffman, ZA Abassi
The Journal of pharmacology and experimental therapeutics 2008
Hormonal control of the renal immune response and antibacterial host defense by arginine vasopressin
C Chassin, MW Hornef, M Bens, M Lotz, JM Goujon, S Vimont, G Arlet, A Hertig, E Rondeau, A Vandewalle
Journal of Experimental Medicine 2007
Small-Molecule Vasopressin-2 Receptor Antagonist Identified by a G-Protein Coupled Receptor “Pathway” Screen
B Yangthara, A Mills, V Chatsudthipong, L Tradtrantip, AS Verkman
Molecular pharmacology 2007
Effect of YM218, a nonpeptide vasopressin V1A receptor-selective antagonist, on rat mesangial cell hyperplasia and hypertrophy
A Tahara, J Tsukada, Y Tomura, T Suzuki, T Yatsu, M Shibasaki
Vascular Pharmacology 2007
Hormonal control of the renal immune response and antibacterial host defense by arginine vasopressin
C Chassin, MW Hornef, M Bens, M Lotz, JM Goujon, S Vimont, G Arlet, A Hertig, E Rondeau, A Vandewalle
Journal of Experimental Medicine 2007
Biological characterization of rodent and human vasopressin V 1b receptors using SSR-149415, a nonpeptide V 1b receptor ligand
CS Gal, D Raufaste, S Derick, J Blankenstein, J Allen, B Pouzet, M Pascal, J Wagnon, MA Ventura
American Journal of Physiology - Regulatory, Integrative and Comparative Physiology 2007
Sex difference in urine concentration across differing ages, sodium intake, and level of kidney disease
J Perucca, N Bouby, P Valeix, L Bankir
American Journal of Physiology - Regulatory, Integrative and Comparative Physiology 2007
Functional rescue of vasopressin V2 receptor mutants in MDCK cells by pharmacochaperones: relevance to therapy of nephrogenic diabetes insipidus
JH Robben, M Sze, NV Knoers, PM Deen
American journal of physiology. Renal physiology 2007
Molecular Mechanisms of Antidiuretic Effect of Oxytocin
C Li, W Wang, SN Summer, TD Westfall, DP Brooks, S Falk, RW Schrier
Journal of the American Society of Nephrology : JASN 2007
Vasopressin receptor antagonists
A Greenberg, JG Verbalis
Kidney International 2006
Vasopressin &#38; Oxytocin
SP Alexander, A Mathie, JA Peters
British Journal of Pharmacology 2006
Kinetic and Theoretical Studies of a Facile, One-Pot Preparation of a Spirocyclohexylindolinone Derivative
A Sánta-Csutor, Z Mucsi, Z Finta, C Gönczi, J Halász, É Csikós, I Hermecz
European Journal of Organic Chemistry 2006
Binding and Signal Transduction Characteristics of the Nonpeptide Vasopressin V<sub>1A</sub> Receptor-Selective Antagonist YM218 in Cultured Rat Mesangial Cells
A Tahara, J Tsukada, Y Tomura, T Kusayama, K Momose, N Taniguchi, T Suzuki, T Yatsu, M Shibasaki
Pharmacology 2006
Hyponatremia in the Neurosurgical Patient: Epidemiology, Pathophysiology, Diagnosis, and Management
JF Fraser, PE Stieg
Neurosurgery 2006
Vaptans and the Treatment of Water-Retaining Disorders
F Quittnat, P Gross
Seminars in Nephrology 2006
Effects of YM218, a nonpeptide vasopressin V1A receptor-selective antagonist, on vasopressin-induced growth responses in human mesangial cells
A Tahara, J Tsukada, Y Tomura, K Momose, T Suzuki, T Yatsu, M Shibasaki
European Journal of Pharmacology 2006
Vasopressin Antagonists as Aquaretic Agents for the Treatment of Hyponatremia
C Palm, F Pistrosch, K Herbrig, P Gross
The American Journal of Medicine 2006
Effects of long-term oral treatment with selective vasopressin V2 receptor antagonist (OPC-31260) on adriamycin-induced heart failure in rats
M Takeuchi, JD Lee, H Shimizu, T Ueda
International Journal of Cardiology 2006
Hyponatremia in cirrhosis: clinical features and management
M Martín-Llahí, M Guevara, P Ginès
Gastroentérologie Clinique et Biologique 2006
Studies on the chemistry of thienoanellated O,N- and S,N-containing heterocycles. Part 30: Synthesis and pharmacological properties of thieno[2,3-b][1,4]thiazines with potential vasopressin receptor antagonistic activity
ME Galanski, T Erker, N Handler, R Lemmens-Gruber, M Kamyar, CR Studenik
Bioorganic & Medicinal Chemistry 2006
Pharmacological Chaperone Activity of SR49059 to Functionally Recover Misfolded Mutations of the Vasopressin V 1a Receptor
SR Hawtin
The Journal of biological chemistry 2006
Posttranscriptional control of aquaporin-2 abundance by vasopressin in renal collecting duct principal cells
U Hasler, S Nielsen, E Féraille, PY Martin
American journal of physiology. Renal physiology 2006
Regulation of UT-A1-mediated transepithelial urea flux in MDCK cells
O Fröhlich, JD Klein, PM Smith, JM Sands, RB Gunn
American journal of physiology. Cell physiology 2006
Probing the Existence of G Protein-Coupled Receptor Dimers by Positive and Negative Ligand-Dependent Cooperative Binding
L Albizu, MN Balestre, C Breton, JP Pin, M Manning, B Mouillac, C Barberis, T Durroux
Molecular pharmacology 2006
An Overview of SSR149415, a Selective Nonpeptide Vasopressin V1b Receptor Antagonist for the Treatment of Stress‐Related Disorders
Gal CS, Wagnon J, Tonnerre B, Roux R, Garcia G, Griebel G, Aulombard A
CNS Drug Reviews 2006
Influence of enantiomers of 1-naphthylalanine in position 2 of VAVP and dVAVP on their pharmacological properties
I Derdowska, A Prahl, W Kowalczyk, M Janecki, S Melhem, HI Trzeciak, B Lammek
European Journal of Medicinal Chemistry 2005
Effects of YM218, a nonpeptide vasopressin V1A receptor-selective antagonist, on human vasopressin and oxytocin receptors
A Tahara, J Tsukada, Y Tomura, T Kusayama, K Wada, N Ishii, N Taniguchi, T Suzuki, T Yatsu, W Uchida, M Shibasaki
Pharmacological Research 2005
An Overview of SSR149415, a Selective Nonpeptide Vasopressin V1b Receptor Antagonist for the Treatment of Stress-Related Disorders
CS Gal, J Wagnon, B Tonnerre, R Roux, G Garcia, G Griebel, A Aulombard
CNS Drug Reviews 2005
Pharmacologic properties of YM218, a novel, potent, nonpeptide vasopressin V1A receptor-selective antagonist
J Tsukada, A Tahara, Y Tomura, T Kusayama, K Wada, N Ishii, N Taniguchi, T Suzuki, T Yatsu, W Uchida, M Shibasaki
Vascular Pharmacology 2005
Intravenous administration of conivaptan hydrochloride improves cardiac hemodynamics in rats with myocardial infarction-induced congestive heart failure
K Wada, A Fujimori, U Matsukawa, Y Arai, K Sudoh, T Yatsu, M Sasamata, K Miyata
European Journal of Pharmacology 2005
High-Throughput Screening of G Protein-Coupled Receptor Antagonists Using a Bioluminescence Resonance Energy Transfer 1-Based β-Arrestin2 Recruitment Assay
FF Hamdan, M Audet, P Garneau, J Pelletier, M Bouvier
Journal of biomolecular screening 2005
An overview of SSR149415, a selective nonpeptide vasopressin V(1b) receptor antagonist for the treatment of stress-related disorders
Claudine Serradeil-Le Gal, Jean Wagnon 3rd, Bernard Tonnerre, Richard Roux, Georges Garcia, Guy Griebel, Alain Aulombard
CNS Drug Reviews 2005
Key Amino Acids Located within the Transmembrane Domains 5 and 7 Account for the Pharmacological Specificity of the Human V1b Vasopressin Receptor
S Derick, A Pena, T Durroux, J Wagnon, CS Gal, M Hibert, D Rognan, G Guillon
Molecular Endocrinology 2004
SSR126768A (4-Chloro-3-[(3 R )-(+)-5-chloro-1-(2,4-dimethoxybenzyl)-3-methyl-2- oxo-2,3-dihydro-1 H -indol-3-yl]- N -ethyl- N -(3-pyridylmethyl)-benzamide, Hydrochloride): A New Selective and Orally Active Oxytocin Receptor Antagonist for the Prevention of Preterm Labor
CS Gal, G Valette, L Foulon, G Germain, C Advenier, E Naline, M Bardou, JP Martinolle, B Pouzet, D Raufaste, C Garcia, E Double-Cazanave, M Pauly, M Pascal, A Barbier, B Scatton, JP Maffrand, GL Fur
The Journal of pharmacology and experimental therapeutics 2004
Vasopressin-independent renal urinary concentration: Increased rBSC1 and enhanced countercurrent multiplication
M Michimata, K Mizukami, M Suzuki, I Kazama, Y Nakamura, K Suzuki, T Yanagisawa, Y Imai, S Sasaki, M Matsubara
Kidney International 2003
Pathophysiological roles of arginine vasopressin and aquaporin-2 in impaired water excretion
S Ishikawa, RW Schrier
Clinical Endocrinology 2003
Cyclic AMP is sufficient for triggering the exocytic recruitment of aquaporin-2 in renal epithelial cells
D Lorenz, A Krylov, D Hahm, V Hagen, W Rosenthal, P Pohl, K Maric
EMBO reports 2003
Disorders of body water homeostasis
JG Verbalis
Best Practice & Research Clinical Endocrinology & Metabolism 2003
Vasopressin-induced facilitation of adrenergic responses in the rat mesenteric artery is V1-receptor dependent
JO Streefkerk, M Pfaffendorf, PA van Zwieten
Autonomic and Autacoid Pharmacology 2003
Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management
V Arroyo, J Colmenero
Journal of Hepatology 2003
Vasopressin: a new target for the treatment of heart failure
CR Lee, ML Watkins, JH Patterson, W Gattis, CM O’Connor, M Gheorghiade, KF Adams
American Heart Journal 2003
Conformational analysis of four spiro[cyclohexane-1,3′-indolin]-2′-one derivatives
J Halász, B Podányi, A Sánta-Csutor, Z Böcskei, K Simon, M Hanusz, I Hermecz
Journal of Molecular Structure 2003
Distúrbios na secreção e ação do hormônio antidiurético
LA Naves, L Vilar, AC Costa, L Domingues, LA Casulari
Arquivos brasileiros de endocrinologia e metabologia 2003
Pancreatic vasopressin V 1b receptors: characterization in In-R1-G9 cells and localization in human pancreas
V Folny, D Raufaste, L Lukovic, B Pouzet, P Rochard, M Pascal, CS Gal
American journal of physiology. Endocrinology and metabolism 2003
Vasopressin Receptor Antagonists: Therapeutic Potential in the Management of Acute and Chronic Heart Failure
SD Russell, T DeWald
American Journal Cardiovascular Drugs 2003
Recent discovery and development of non-peptide vasopressin V2receptor agonists
K Kondo
Expert Opinion on Therapeutic Patents 2002
The Effects of Several Vasopressin Receptor Antagonists on Normal Intraocular Pressure and the Intraocular Distribution of Vasopressin Receptor Subtypes
A Naito, T Kurasawa, Y Ohtake, Y Toyoda, Y Ezure, K Koike, K Shigenobu
Biological & Pharmaceutical Bulletin 2002
Pharmacological characterization of F-180: a selective human V1avasopressin receptor agonist of high affinity
M Andrés, M Trueba, G Guillon
British Journal of Pharmacology 2002
Vasopressin-induced presynaptic facilitation of sympathetic neurotransmission in the pithed rat
JO Streefkerk, MJ Mathy, M Pfaffendorf, PA van Zwieten
Journal of Hypertension 2002
Effect of YM471, a nonpeptide AVP receptor antagonist, on human coronary artery smooth muscle cells
A Tahara, J Tsukada, Y Tomura, K Wada, T Kusayama, N Ishii, T Yatsu, W Uchida, N Taniguchi, A Tanaka
Peptides 2002
Pharmacological characterization of YM471, a novel potent vasopressin V1A and V2 receptor antagonist
J Tsukada, A Tahara, Y Tomura, K Wada, T Kusayama, N Ishii, M Aoki, T Yatsu, W Uchida, N Taniguchi, A Tanaka
European Journal of Pharmacology 2002
Arginine vasopressin modulates expression of neuronal NOS in rat renal medulla
PY Martin, M Bianchi, F Roger, L Niksic, E Féraille
American journal of physiology. Renal physiology 2002
Pharmacodynamic effects of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascites
D Guyader
Hepatology 2002
Characterization of (2 S ,4 R )-1-[5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1 H -indol-3-yl]-4-hydroxy- N , N -dimethyl-2-pyrrolidine carboxamide (SSR149415), a Selective and Orally Active Vasopressin V 1b Receptor Antagonist
CS Gal, J Wagnon, J Simiand, G Griebel, C Lacour, G Guillon, C Barberis, G Brossard, P Soubrié, D Nisato, M Pascal, R Pruss, B Scatton, JP Maffrand, GL Fur
The Journal of pharmacology and experimental therapeutics 2002
NEPHROGENICDIABETESINSIPIDUS
JP Morello, DG Bichet
Annual Review of Physiology 2001
Treatment of severe hyponatremia
P Gross
Kidney International 2001
Effects of YM471, a nonpeptide AVP V1Aand V2receptor antagonist, on human AVP receptor subtypes expressed in CHO cells and oxytocin receptors in human uterine smooth muscle cells
J Tsukada, A Tahara, Y Tomura, W Ki, T Kusayama, N Ishii, T Yatsu, W Uchida, N Taniguchi, A Tanaka
British Journal of Pharmacology 2001
THEBASIC ANDCLINICALPHARMACOLOGY OFNONPEPTIDEVASOPRESSINRECEPTORANTAGONISTS
M Thibonnier, P Coles, A Thibonnier, M Shoham
Annual Review of Pharmacology and Toxicology 2001
A nonpeptide vasopressin V1a receptor antagonist, SR 49059, does not prevent cisplatin-induced emesis in piglets
L Grelot, V Girod, J Dapzol, JP Maffrand, CS Gal
Fundamental and Clinical Pharmacology 2001
An Overview of SR121463, a Selective Non-Peptide Vasopressin V2 Receptor Antagonist
CS Gal
Cardiovascular Drug Reviews 2001
Chronic exposure to vasopressin upregulates ENaC and sodium transport in the rat renal collecting duct and lung
C Nicco, M Wittner, A DiStefano, S Jounier, L Bankir, N Bouby
Hypertension 2001
Single Amino Acid Substitutions and Deletions That Alter the G Protein Coupling Properties of the V2 Vasopressin Receptor Identified in Yeast by Receptor Random Mutagenesis
I Erlenbach, E Kostenis, C Schmidt, CS Gal, D Raufaste, ME Dumont, MH Pausch, J Wess
The Journal of biological chemistry 2001
Selective blockade of vasopressin V2 receptors reveals significant V2‐mediated water reabsorption in Brattleboro rats with diabetes insipidus
B Pouzet, CS Gal, N Bouby, JP Maffrand, GL Fur, L Bankir
Nephrology Dialysis Transplantation 2001
Total Synthesis of SR 121463 A, a Highly Potent and Selective Vasopressin V 2 Receptor Antagonist
H Venkatesan, MC Davis, Y Altas, JP Snyder, DC Liotta
The Journal of Organic Chemistry 2001
Glomerular Injury and Tubular Loss in Adriamycin Nephrosis
B Javaid, JL Olson, TW Meyer
Journal of the American Society of Nephrology : JASN 2001
Molecular modeling of interactions of the non-peptide antagonist YM087 with the human vasopressin V1a, V2 receptors and with oxytocin receptors
A Giełdoń, R Kaźmierkiewicz, R Slusarz, J Ciarkowski
Journal of Computer-Aided Molecular Design 2001
Vasopressin-induced von Willebrand factor secretion from endothelial cells: involvement of V2 receptors and cAMP
Jocelyne E. Kaufmann, Alexander Oksche, Claes B. Wollheim, Gabriele Gunther, Walter Rosenthal, Ulrich M. Vischer
Journal of Clinical Investigation 2000
Generation and phenotype of mouse strains harboring a nonsense mutation within the V2 vasopressin receptor coding sequence
June Yun, Torsten Schoneberg, Jie Liu, Angela Schulz, Carolyn A.Ecelbarger,Dominique Promeneur,Soren Nielson,Hui Sheng, Alexander Grinberg, Chu-xia Deng, Jurgen Wess
Journal of Clinical Investigation 2000
Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants
JP Morello, A Salahpour, A Laperrière, V Bernier, MF Arthus, M Lonergan, U Petäjä-Repo, S Angers, D Morin, DG Bichet, M Bouvier
Journal of Clinical Investigation 2000
Characterization of a novel nonpeptide vasopressin V2-agonist, OPC-51803, in cells transfected human vasopressin receptor subtypes
S Nakamura, Y Yamamura, S Itoh, T Hirano, K Tsujimae, M Aoyama, K Kondo, H Ogawa, T Shinohara, K Kan, Y Tanada, S Teramoto, T Sumida, S Nakayama, K Sekiguchi, T Kambe, G Tsujimoto, T Mori, M Tominaga
British Journal of Pharmacology 2000
Pharmacologic characterization of the oxytocin receptor in human uterine smooth muscle cells
A Tahara, J Tsukada, Y Tomura, K Wada, T Kusayama, N Ishii, T Yatsu, W Uchida, A Tanaka
British Journal of Pharmacology 2000
Binding properties of a selective tritiated vasopressin V2 receptor antagonist, [3H]-SR 121463
CS Gal, D Raufaste, E Double-Cazanave, G Guillon, C Garcia, M Pascal, JP Maffrand
Kidney International 2000
Vasopressin receptor antagonism - a therapeutic option in heart failure and hypertension
LM Burrell, J Risvanis, CI Johnston, M Naitoh, LC Balding
Experimental Physiology 2000
Nephrogenic diabetes insipidus
PM Deen, N Marr, EJ Kamsteeg, BW van Balkom
Current Opinion in Nephrology and Hypertension 2000
The treatment of hyponatraemia using vasopressin antagonists
P Gross, C Palm
Experimental Physiology 2000
Pharmacological chaperones: a new twist on receptor folding
JP Morello, M Bouvier, UE Petäjä-Repo, DG Bichet
Trends in Pharmacological Sciences 2000
Effect of SR121463, a Selective Non-Peptide Vasopressin V2Receptor Antagonist, in a Rabbit Model of Ocular Hypertension
F Lacheretz, A Barbier, CS Gal, PP Elena, JP Maffrand, GL Fur
Journal of Ocular Pharmacology and Therapeutics 2000
Conserved aromatic residues in the transmembrane region VI of the V1a vasopressin receptor differentiate agonist vs. antagonist ligand binding
N Cotte, MN Balestre, A Aumelas, E Mahé, S Phalipou, D Morin, M Hibert, M Manning, T Durroux, C Barberis, B Mouillac
European Journal of Biochemistry 2000
Aquaretic and hormonal effects of a vasopressin V2 receptor antagonist after acute and long-term treatment in rats
C Lacour, G Galindo, F Canals, D Segondy, C Cazaubon, CS Gal, A Roccon, D Nisato
European Journal of Pharmacology 2000
Hyponatremia
HJ Adrogué, NE Madias
New England Journal of Medicine 2000
Complications of cirrhosis. II. Renal and circulatory dysfunction. Lights and shadows in an important clinical problem
V Arroyo, W Jiménez
Journal of Hepatology 2000
Vasopressin V 2 -receptor-dependent regulation of AQP2 expression in Brattleboro rats
D Promeneur, TH Kwon, J Frøkiær, MA Knepper, S Nielsen
American journal of physiology. Renal physiology 2000
Polarized expression of the vasopressin V2 receptor in Madin-Darby canine kidney cells
B Andersen-Beckh, M Dehe, R Schulein, B Wiesner, C Rutz, U Liebenhoff, W Rosenthal, A Oksche
Kidney International 1999
Aquaretics
M Thibonnier
Expert Opinion on Emerging Drugs 1999
In vivo and in vitro characterisation of a nonpeptide vasopressin V1A and V2 receptor antagonist (YM087) in the rat
J Risvanis, M Naitoh, CI Johnston, LM Burrell
European Journal of Pharmacology 1999
Vasopressin increases vascular endothelial growth factor secretion from human vascular smooth muscle cells
A Tahara, M Saito, J Tsukada, N Ishii, Y Tomura, K Wada, T Kusayama, T Yatsu, W Uchida, A Tanaka
European Journal of Pharmacology 1999
PHARMACOLOGICAL PROFILE OF ORALLY ADMINISTERED YM087, A VASOPRESSIN ANTAGONIST, IN CONSCIOUS RATS
Y Tomura, A Tahara, J Tsukada, T Yatsu, W Uchida, YI Honda
Clinical and Experimental Pharmacology and Physiology 1999
Receptor binding of oxytocin and vasopressin antagonists and inhibitory effects on isolated myometrium from preterm and term pregnant women
M Akerlund, T Bossmar, R Brouard, A Kostrzewska, T Laudanski, A Lemancewicz, CS Gal, M Steinwall
BJOG: An International Journal of Obstetrics and Gynaecology 1999
V1a- and V2-type vasopressin receptors mediate vasopressin-induced Ca2+ responses in isolated rat supraoptic neurones
L Gouzénes, N Sabatier, P Richard, FC Moos, G Dayanithi
The Journal of Physiology 1999
Vasopressin contributes to hyperfiltration, albuminuria, and renal hypertrophy in diabetes mellitus: study in vasopressin-deficient Brattleboro rats
P Bardoux, H Martin, M Ahloulay, F Schmitt, N Bouby, MM Trinh-Trang-Tan, L Bankir
Proceedings of the National Academy of Sciences 1999
Vasopressin V2 (SR121463A) and V1a (SR49059) receptor antagonists both inhibit desmopressin vasorelaxing activity
I Méchaly, F Laurent, K Portet, JJ Serrano, G Cros
European Journal of Pharmacology 1999
Comparison of vasopressin binding sites in human uterine and vascular smooth muscle cells
A Tahara, J Tsukada, N Ishii, Y Tomura, K Wada, T Kusayama, T Yatsu, W Uchida, A Tanaka
European Journal of Pharmacology 1999
Characterization of rodent liver and kidney AVP receptors: pharmacologic evidence for species differences
A Tahara, J Tsukada, N Ishii, Y Tomura, K Wada, T Kusayama, T Yatsu, W Uchida, A Tanaka
Regulatory Peptides 1999
Vasopressin contributes to hyperfiltration, albuminuria, and renal hypertrophy in diabetes mellitus: Study in vasopressin-deficient Brattleboro rats
P Bardoux, H Martin, M Ahloulay, F Schmitt, N Bouby, MM Trinh-Trang-Tan, L Bankir
Proceedings of the National Academy of Sciences 1999
7-Chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-1-benzazepine (OPC-41061): A potent, orally active nonpeptide arginine vasopressin V2 receptor antagonist
K Kondo, H Ogawa, H Yamashita, H Miyamoto, M Tanaka, K Nakaya, K Kitano, Y Yamamura, S Nakamura, T Onogawa, T Mori, M Tominaga
Bioorganic & Medicinal Chemistry 1999
Neurologische Intensivmedizin
S Schwab, D Krieger, W Müllges, G Hamann, W Hacke
1999
V2-vasopressin receptor antagonists—mechanism of effect and clinical implications in hyponatraemia
C Palm, P Gross
Nephrology Dialysis Transplantation 1999
Hyponatremia in cirrhosis: From pathogenesis to treatment
P Gin�s, T Berl, M Bernardi, DG Bichet, G Hamon, W Jim�nez, JF Liard, PY Martin, RW Schrier
Hepatology 1998
Pharmacological characterization of the human vasopressin receptor subtypes stably expressed in Chinese hamster ovary cells
A Tahara, M Saito, T Sugimoto, Y Tomura, K Wada, T Kusayama, J Tsukada, N Ishii, T Yatsu, W Uchida, A Tanaka
British Journal of Pharmacology 1998
Development and therapeutic indications of orally-active non-peptide vasopressin receptor antagonists
M Thibonnier
Expert Opinion on Investigational Drugs 1998
Binding Characteristics of YM087, an AVP Receptor Antagonist, in Rhesus Monkey Liver and Kidney Membranes
A Tahara, Y Tomura, K Wada, T Kusayama, J Tsukada, N Ishii, T Yatsu, W Uchida, A Tanaka
Peptides 1998
Stability of the vasopressin V2 receptor–adenylyl cyclase system in rat kidney
T Shen, J Laycock, Y Suzuki, N Defer, J Hanoune
European Journal of Pharmacology 1998
The D136A mutation of the V2 vasopressin receptor induces a constitutive activity which permits discrimination between antagonists with partial agonist and inverse agonist activities
D Morin, N Cotte, MN Balestre, B Mouillac, M Manning, C Breton, C Barberis
FEBS Letters 1998
Acute effects of vasopressin V 2 -receptor antagonist on kidney AQP2 expression and subcellular distribution
BM Christensen, D Marples, UB Jensen, J Frøkiaer, D Sheikh-Hamad, M Knepper, S Nielsen
American journal of physiology. Renal physiology 1998
Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced protein synthesis in neonatal rat cardiomyocyte
A Tahara, Y Tomura, K Wada, T Kusayama, J Tsukada, N Ishii, T Yatsu, W Uchida, A Tanaka
Cardiovascular Research 1998
Identification of Residues Responsible for the Selective Binding of Peptide Antagonists and Agonists in the V2 Vasopressin Receptor
N Cotte, MN Balestre, S Phalipou, M Hibert, M Manning, C Barberis, B Mouillac
The Journal of biological chemistry 1998
Vasopressin and Oxytocin
HH Zingg, CW Bourque, DG Bichet
1998
A Prospective Study of Patients with Lung Cancer and Hyponatremia of Malignancy
BE Johnson, JP Chute, J Rushin, J Williams, PT Le, D Venzon, GE Richardson
American journal of respiratory and critical care medicine 1997
Characterization and localization of leptin receptors in the rat kidney
C Serradeil-Le Gal, D Raufaste, G Brossard, B Pouzet, E Marty, J P Maffrand, G Le Fur
FEBS Letters 1997
Low urine flow reduces the capacity to excrete a sodium load in humans
G Choukroun, F Schmitt, F Martinez, TB Drüeke, L Bankir
American Journal of Physiology - Regulatory, Integrative and Comparative Physiology 1997
G Protein-Coupled Receptors
TP Iismaa, TJ Biden, J Shine
1995
Progress in Brain Research
DE van Epps, L Saland, C Taylor, RC Williams
Progress in brain research 1983

← Previous 1 2 3 … 7 8 Next →

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 5 patents
31 readers on Mendeley
See more details